Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05286619 | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)(PIPER) | recruiting | Phase 2 | 63 | University of MalayaOTHER | 1 | Oct 15, 2024 |
| clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05014464 | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase) | recruiting | Phase 2 | 90 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06344052 | To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | recruiting | Phase 2 | 80 | Stamford Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06355609 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW(WUKONG-32-RW) | recruiting | Phase 2 | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05379803 | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | recruiting | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 100 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06141226 | Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 148 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06348927 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC(WUKONG-32) | recruiting | Phase 2 | 52 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06527898 | Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06603376 | Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer | recruiting | Phase 2 | 75 | Shanghai Changzheng HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06501391 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis | recruiting | Phase 2 | 54 | Fudan UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06572514 | De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC | recruiting | Phase 1 / Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06007729 | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06562920 | Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer(Neoadjuvant) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06560528 | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06100497 | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06393816 | FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum(FIRST-NEC) | recruiting | Phase 2 | 80 | Centre Leon BerardOTHER | 2 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05913427 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)(PESETA) | recruiting | Phase 2 | 80 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06528847 | Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma | recruiting | Phase 2 | 62 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06394674 | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib | recruiting | Phase 2 | 84 | Changhai HospitalOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | recruiting | Phase 2 | 96 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06492421 | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 162 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 16, 2024source: clinicaltrials